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The complexity of developing and applying increasingly sophisticated new medicinal
products has led to the participation of many non-medically qualified scientists in
multi-disciplinary non-clinical and clinical drug development teams world-wide. In this
introductory paper to the “IFAPP International Ethics Framework for Pharmaceutical
Physicians and Medicines Development Scientists” it is argued that all members of
such multidisciplinary teams must share the scientific and ethical responsibilities since
they all influence directly or indirectly both the outcome of the various phases of the
medicines development projects and the safety of the research subjects involved. The
participatingmedical practitioner retains the overriding responsibility and the final decision
to stop a trial if the well-being of the research subjects is seriously endangered. All the
team members should follow the main ethical principles governing human research,
the respect for autonomy, justice, beneficence and non-maleficence. Nevertheless, the
weighing of these principles might be different under various conditions according to the
specialty of the members.
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For hundreds of years, treatments based on experience formed a continuum with uncontrolled
individual therapeutic trials performed by the treating physicians in the hope of helping their
patients. The deep ethical concern of the practicing physicians is expressed with great clarity by
WilliamWithering who introduced digitalis into medical practice in the 18th century: “After all, in
spite of opinion, prejudice or error, Time will fix the real value upon this discovery, and determine
whether I have imposed upon myself and others, or contributed to the benefit of science and
mankind.” (Eichhorn and Gheorghiade, 2002).
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The major shift toward prospective clinical trials can be
traced back to the end of the nineteenth century when major
hospitals were founded where trained medical personnel could
perform well planned clinical trials. In addition, the creation
of medical journals meant that the results could be rapidly
communicated to other medical teams working world-wide,
creating an international background for establishing common
norms for accepted medical practice. Unfortunately, in the
rapidly changing medical research environment some physicians
performed human experiments which clearly violated the broadly
accepted ethical principles of society. During this period
the German scientific community, represented by outstanding
clinical scientists such as Rudolf Virchow, Robert Koch, Paul
Ehrlich, and Emil von Behring made breakthrough contributions
to medicine.
It is therefore not surprising that the first regulation of
clinical experiments was penned in Germany in 1901 (Erlass der
Preussischen Regierung vom Dezember, 1901) in which most of
the major ethical issues of clinical research at the time were listed.
The complexity of contemporary medical interventions could
be relatively easily managed by the clinicians without extensive
support of other non-medically qualified experts. Accordingly,
it was a reasonable decision by the law makers to place the
entire ethical responsibility on the head of the medical team and
proclaim that it was the duty of the senior chief physician to
evaluate both the scientific and ethical aspects of the research
plan and supervise its execution according to Hippocratic Oath
governed primarily by the maxim “primum non-nocere.”
In practical terms the responsibility for the safety and well-
being of the trial subject means that the ethical responsibility
is essentially also the burden of the medical profession. It is
explicitly stated in the Declaration of Helsinki: “It is the duty of
physicians who are involved in medical research to protect the
life, health, dignity, integrity, right to self-determination, privacy
and confidentiality of personal information of research subjects.”
(WMA Declaration of Helsinki, 2013).
It has been tacitly assumed that the ethical guidance will
be followed by the other non-medically qualified personnel.
This strong relation of human research to the human health
field and profession has been followed essentially unchallenged
in the other ethical declarations, guidelines and international
agreements dealing with human research published subsequent
to the Nuremberg trial (The Belmont Report, 1979; The Oviedo
Convention, 1997; Good Pharmaceutical Medical Practice,
2014; ICH Harmonised Guideline, 2016; International Ethical
Guidelines for Health-related Research Involving Humans Final
CIOMS, 2016). The ICH Harmonized Guideline refers only
shortly to multidisciplinary research stating that “the investigator
should maintain a list of appropriately qualified persons to whom
the investigator has delegated significant trial-related duties.”
In the CIOMS Guideline prepared in collaboration with the
World Health Organization (WHO) it is only recommended
that sponsors, researchers and research ethics committees “must
ensure that all research personnel are qualified by virtue of
their education and experience to perform competently and with
integrity. This includes receiving appropriate ethics education
and training. Qualifications of research personnel must be
adequately described in the materials submitted to the research
ethics committee.” Rapid scientific progress makes it, however,
questionable whether this narrow approach is tenable, or the
ethical issues should also be specifically addressed with inputs
from other experts specifying also their ethical responsibilities.
Medical treatments became very sophisticated in recent years,
many complex interventions can be performed only with the
support of highly trained but non-medically qualified personnel.
This is of great concern primarily for drug development groups
which investigate for example advanced medicinal products such
as gene and cell therapies, drug andmedical device combinations.
In such multidisciplinary teams the physicians work as team
members, with special ethical responsibility to care for the well-
being of the patients. Therefore, the physicians maintain a well-
defined safeguarding role within the team, although he/she may
no longer be in the position to understand the inputs of the
various professionals in depth. Consequently, the physician of
such teams cannot carry the entire ethical responsibility for the
correct planning and conduct of the clinical trial alone. Inevitably
the society has to decide whether the traditional clinician-
centered ethical guidelines should be maintained or whether
it is time to address the ethical responsibilities of the various
non-medically qualified professionals directly involved as well.
The clinicians and non-medically qualified scientists have
two main fields of interactions in the clinical development
and application of medicines. The first occurs in translational
medicine. The second contact is characterized by strong
multidisciplinary cooperation in the development and
therapeutic application of advanced therapies. As a result
of the increasingly critical interaction of basic scientists with
medical professionals many non-medically qualified scientists
have become members of the IFAPP (2003). At present a large
fraction of the IFAPP membership is not medically qualified,
although pharmaceutical medicine was originally conceived
as a medical discipline. It is a logical further step, that IFAPP
decided to consider the ethical aspects of this collaboration and
started to characterize the ethical responsibilities of the many
non-clinicians involved in the research and clinical application
of modern complex therapies. Supplementary Material: IFAPP
International Ethics Framework for Pharmaceutical Physicians
and Medicines Development Scientists, 2018.
Translational medicine provides a scientific bridge connecting
non-clinical studies with the early exploratory evaluation of
an investigational medicinal agent in humans (Littman et al.,
2007). In reality, drug development gradually became part
of an enlarged concept of pharmaceutical medicine. The
safe and effective transfer of basic research results into the
human research phase became a primary concern. New drug
targets and biomarkers, the development of drug-medical
device combinations, the methods of the preparation and
administration of gene or cellular medicinal products are usually
first investigated in animals by academic research groups. It
is therefore very disappointing that from 53 landmark studies
published in prestigious journals only 6% reported sufficiently
robust data to drive reliably human medicines development
programs (Begley and Ellis, 2012). Similarly, from 67 projects
evaluated by a company 65% of the results published in the
scientific literature could not be reproduced (Prinz et al., 2011).
The broad experience of industrial R&D experts indicates that
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around 50% of findings published cannot be reproduced by
the pharmaceutical industry (Booth, 2011). The inability of
industry and clinical trial groups to reproduce the results of
many academic publications on potential therapeutic targets
and biomarkers suggests a general systemic problem, although
occasional fraud cannot be ruled out.
Promising pre-clinical testing results frequently lead to rapid
clinical development without thoroughly evaluating the quality
of the data and the reproducibility of the experiments. This
practice might lead, in unfortunate cases, to serious human
suffering and wasting of valuable clinical resources. Superficially
performed and/or interpreted animal-human translation studies
might be considered one of the main components leading to
system failures occurring in human phase I studies. Examples
of two recent early clinical trial tragedies caused by TGN-
1412 (TeGenero Immuno Therapeutics AG), (Reason, 2000;
Suntharalingam et al., 2006; Sims, 2009; Attarwala, 2010),
and by BIA 10-2474 (Bial-Portela & Ca. SA.) (Kerbrat
et al., 2016; Greenberg et al., 2017) reminded the scientific
community of the consequences for involved human beings.
It became a main ethical requirement for effective and safe
human drug development, that academic scientists should
adopt research methods similar to those used in clinical trials
to significantly improve construct validity of their research,
especially the internal and external validities of the confirmatory
pharmacotherapeutic studies in animals (Kilkenny et al., 2010;
van der Worp et al., 2010; Arrowsmith, 2011; Kimmelman
and London, 2011; de Vries et al., 2014; Kimmelman et al.,
2014). With the translational concept animal and human studies
gradually grow together to form a functional continuum. This
bridge effectively binds experts of non-clinical research and
clinical drug development into a functional continuum of
partnership with shared ethical responsibilities. As a logical
consequence it was considered necessary to include the ethical
responsibilities of non-clinical researchers into the new revised
version of the ethical framework of IFAPP.
Multidisciplinary teams gained broad acceptance in drug
development when, beside the determination of clinical efficacy
and safety, the correlations between the plasma level of the
drugs and their pharmacodynamic effects also became the
additional focus of clinical pharmacological investigations.
Such cooperation is primarily characterized by the parallel
work of the clinical and various non-medical experts who
perform pharmacokinetic, biochemical, immunological
and other investigations on human samples. The ethical
problems of such cooperation are usually limited to the
amount and frequency of the sampling of human materials
needed for conducting the studies. The situations can be
handled by finding a scientifically acceptable compromise
which does not cause additional harm for the human
subjects. A conceptually entirely different and much
more sophisticated cooperation becomes necessary for
investigating and applying advanced therapeutic products
in patients.
The complexity of the scientific-medical approach can be
convincingly demonstrated in the case of the recently developed
Chimeric Antigen Receptor Adoptive T-cell (CAR-T) cancer
therapy. For this treatment the genes coding for the specific
CAR-T receptor recognizing the cancer surface antigen(s) of the
individual patients must be transferred into the harvested T-cells
of the patients. The modified T-cells are then further incubated
in vitro before re-transfusion for reaching the required number
of modified T-cells for effective tumor kill. The production of
the individually prepared targeted medicinal product is carried
out under Good Manufacturing Practice (GMP) conditions by
a multidisciplinary expert team specialized in immunology, cell
and molecular biology (Jacobson and Ritz, 2011; Yee, 2013;
Sharpe and Mount, 2015; Hartmann et al., 2017). The therapy
is a real team effort. The final therapeutic decisions must be
made jointly by all the experts involved considering both the
condition of the patient as well as the success and specificity
of the CAR-T cell preparation to be used for the individualized
therapy.
In such multidisciplinary teams the physician is only one
member with a specific right to stop the intervention if
the safety of the patient is endangered and the interruption
of the therapy does not cause additional harm. It is not
surprising that the FDA requires that the entire staff involved
in this complex therapy should be specifically trained and
certified (FDA News Release, 2017). The joint scientific-ethical
responsibility of such a multidisciplinary team is obvious.
Although it is assumed that all experts act according to the basic
principles governing human research, respect for autonomy,
beneficence, non-maleficence and justice (Beauchamp and
Childress, 2012), different weighing of these principles might
be expected under different conditions (Ebbesen and Pedersen,
2007; Page, 2012). Such differences must be resolved within
the group for each case separately. To maintain successful
cooperation, it must be ensured that each contributor is able to
work according to the guiding principles of their professional
organizations.
The rapid progress of advanced therapies will further increase
the need for including many different professionals into clinical
teams. In addition, new scientific knowledge continuously
generates unforeseen ethical problems. For successfully
managing increasingly sophisticated ethical challenges IFAPP
recommends and plans to contribute to the strengthening
education of ethics at the under-graduate and post-graduate
levels both for medical and other biomedical professionals.
The aim of the linked IFAPP International Ethics
Framework is to highlight the ethical issues relevant to
the increasingly close cooperation of physicians and non-
medically qualified experts in human drug development and
application. Supplementary Material: IFAPP International
Ethics Framework for Pharmaceutical Physicians and Medicines
Development Scientists, 2018. The intention of the IFAPP
Working Group on Ethics was to provide recommendations
for supporting both medically and non-medically qualified
investigators to make ethical decisions cooperatively under
various, frequently unexpected, situations occurring during
human drug research. We are convinced that the recommended
joint decision-making process will be helpful for all scientists
working all over the world in medicines development to find
ethical answers to new challenges. It is also hoped that the
revised edition of the IFAPP International Ethics Framework
might be helpful for countries either to adjust their local
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recommendations to the new scientific environment or
to introduce ethical guidance if not yet existent in their country.
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